Ogata H, Aoyagi N, Kaniwa N, Shibazaki T, Ejima A, Takasugi N, Mafune E, Hayashi T, Suwa K
Int J Clin Pharmacol Ther Toxicol. 1984 May;22(5):240-5.
The bioavailability of nalidixic acid in beagles was determined using the same tablet formulations previously tested on humans and was compared with bioavailability in humans and with in vitro dissolution rates. The beagle bioavailability test provided lower power in all of the bioavailability parameters than did the human test. Tmax of the tablets did not greatly differ in beagles, although in humans a wide variation of Tmax was seen. A linearity between Cmax and AUC0-infinity was observed in beagles, but Tmax did not show a linearity with Cmax or AUC in dogs, which is quite different from the relations observed in humans. The rank order of tablets according to Cmax was exactly the same between humans and beagles. AUC also showed the same rank order between humans and beagles except for on tablet with a poor disintegrating ability. A significant correlation between human and beagle Cmax values was obtained (r = 0.8952; p less than 0.05), but not between human and beagle AUC and Tmax values.
使用先前在人体上测试过的相同片剂配方测定了萘啶酸在比格犬中的生物利用度,并将其与人体中的生物利用度以及体外溶出速率进行了比较。比格犬的生物利用度试验在所有生物利用度参数方面提供的效能均低于人体试验。片剂的达峰时间(Tmax)在比格犬中差异不大,尽管在人体中观察到达峰时间有很大差异。在比格犬中观察到峰浓度(Cmax)与药时曲线下面积(AUC0-无穷大)之间呈线性关系,但在犬中达峰时间与峰浓度或药时曲线下面积未呈现线性关系,这与在人体中观察到的关系有很大不同。根据峰浓度,人体和比格犬中片剂的排序完全相同。除了一种崩解能力差的片剂外,药时曲线下面积在人体和比格犬中也呈现相同的排序。人体和比格犬的峰浓度值之间获得了显著相关性(r = 0.8952;p < 0.05),但人体和比格犬的药时曲线下面积以及达峰时间值之间未呈现显著相关性。